Results 51 to 60 of about 3,657 (192)

Redefining Therapies for Drug‐Resistant Tuberculosis: Synergistic Effects of Antimicrobial Peptides, Nanotechnology, and Computational Design

Advanced Healthcare Materials, Volume 15, Issue 14, 10 April 2026.
Antimicrobial peptide (AMP)‐loaded nanocarriers provide a multifunctional strategy to combat drug‐resistant Mycobacterium tuberculosis. By enhancing intracellular delivery, bypassing efflux pumps, and disrupting bacterial membranes, this platform restores phagolysosome fusion and macrophage function.
Christian S. Carnero Canales, Jessica Ingrid Marquez Cazorla, Renzo Marianito Marquez Cazorla, Aline Martins dos Santos, Jonatas Lobato Duarte, Letícia Oliveira Catarin Nunes, Túlio Custódio Reis, Lara Cerazi Salvador, Norival Alves Santos‐Filho, Rafael Miguel Sábio, Hélder A. Santos, Fernando Rogério Pavan   +11 more
wiley   +1 more source

Rezultatele tratamentului tuberculozei multidrogrezistente cu utilizarea bedaquiline şi delamanid

Buletinul Academiei de Ştiinţe a Moldovei: Ştiinţe Medicale, 2021
Rezultatele tratamentului tuberculozei multidrogrezistente cu utilizarea bedaquiline şi delamanid Articolul prezintă rezultatele unei analize a eficacităţii şi siguranţei bedaquilinei şi delamanidului la pacienţii cu tuberculoză multidrogrezistentă (TB ...
Rafig Bayramov, Jeyhun Ismayilzada, Orkhan Suleymanov   +2 more
doaj   +1 more source

Adduct Formation of Delamanid with NAD in Mycobacteria

Antimicrobial Agents and Chemotherapy, 2020
Delamanid (DLM), a nitro-dihydroimidazooxazole derivative currently approved for pulmonary multidrug-resistant tuberculosis (TB) therapy, is a prodrug activated by mycobacterial 7,8-didemethyl-8-hydroxy 5-deazaflavin electron transfer coenzyme (F 420 )-dependent nitroreductase (Ddn).
Mikayo Hayashi, Akihito Nishiyama, Ryuki Kitamoto, Yoshitaka Tateishi, Mayuko Osada-Oka, Yukiko Nishiuchi, Shaban A. Kaboso, Xiuhao Chen, Mamoru Fujiwara, Yusuke Inoue, Yoshikazu Kawano, Masanori Kawasaki, Tohru Abe, Tsutomu Sato, Kentaro Kaneko, Kimiko Itoh, Sohkichi Matsumoto, Makoto Matsumoto   +17 more
openaire   +3 more sources

Improving Genotype Imputation in High‐Dimensional Pharmacogenomics Using Multiple Imputation: Evaluation with Machine Learning Approaches

Clinical Pharmacology &Therapeutics, Volume 119, Issue 4, Page 964-978, April 2026.
Multiple imputation is well‐established for handling missing data, yet its use in high‐dimensional genetic datasets remains limited. Using pharmacokinetic tuberculosis simulations and SNP data (1000 Genomes Project), we compared machine learning (ML) and traditional approaches (e.g., mean imputation and complete‐case analysis) for imputation and ...
Innocent G. Asiimwe, Tao You, Daniel F. Carr, Munir Pirmohamed, Geraint Davies, Andrea L. Jorgensen, on behalf of the UNITE4TB Consortium   +6 more
wiley   +1 more source

Exploring Novel Nitrofuryl‐1,3,4‐Thiadiazole‐Based Derivatives: Design, Synthesis, and Evaluation of In Vitro Leishmanicidal and Trypanocidal Activity

Archiv der Pharmazie, Volume 359, Issue 3, March 2026.
In a series of substituted 1‐[5‐(5‐nitrofuran‐2‐yl)‐1,3,4‐thiadiazol‐2‐yl]piperidine‐4‐carboxamides evaluated for in vitro antileishmanial and antitrypanosomal activity, compound 18 emerged as the most promising derivative, showing submicromolar anti‐parasitic effects targeting diverse Leishmania and Trypanosoma species and acceptable selectivity ...
Alireza Mousavi, Martina Slapničková, Maryam Norouzbahari, Sarah D'Alessandro, Parham Foroumadi, Fariba Peytam, Federica Perego, Eva Doleželová, Zahra Emamgholipour, Maliheh Barazandeh Tehrani, Seyed Esmaeil Sadat‐Ebrahimi, Elahe Hosseinzadeh, Elmira Meghrazi Ahadi, Loghman Firoozpour, Hamidreza Bijanzadeh, Nicoletta Basilico, Alena Zíková, Alireza Foroumadi   +17 more
wiley   +1 more source

QTc Interval Prolongation in Drug-Resistant Tuberculosis Treated with Bedaquiline and Delamanid Under Programmatic Conditions

Pharmacology and Clinical Pharmacy Research
Background: The cardiac safety of regimens containing bedaquiline and delamanid is not well-established, especially in Indonesia.  This study aimed to analyze QTc interval during six months of treatment and factors associated with QTc interval ...
Oki Nugraha Putra
doaj   +1 more source

Advances of new drugs bedaquiline and delamanid in the treatment of multi-drug resistant tuberculosis in children

Frontiers in Cellular and Infection Microbiology, 2023
Tuberculosis (TB) is a major public health problem, with nearly 10 million new cases and millions of deaths each year. Around 10% of these cases are in children, but only a fraction receive proper diagnosis and treatment. The spread of drug-resistant (DR)
Hanzhao Zhu, Hanzhao Zhu, Xintong Zhou, Zengfang Zhuang, Zengfang Zhuang, Lianju Li, Lianju Li, Jing Bi, Kaixia Mi, Kaixia Mi   +9 more
doaj   +1 more source

A 9‐Year‐Old Boy With Right‐Sided Extrapulmonary Drug‐Resistant Tuberculosis Subphrenic Abscess: A Case Report From Woldia, Northeast Ethiopia

Clinical Case Reports, Volume 14, Issue 3, March 2026.
Coronal reconstruction post contrast thoraco‐abdominal CT of a 9 years old boy taken December, 2023. This shows 1.45 by 3.9 cms hypodense collection having rim enhancement in the right anterio‐inferior sub‐phrenic space suggestive of abscess. ABSTRACT Diagnosing extrapulmonary and drug‐resistant tuberculosis in children is challenging.
Animaw Lingerew, Samuel Addis, Adugnaw Atnafu, Zeru Siyoum, Solomie Jebessa Deribessa   +4 more
wiley   +1 more source

Relative bioavailability of delamanid 50 mg tablets dispersed in water in healthy adult volunteers

, 2023
Aim Delamanid is a novel drug for the treatment of drug-resistant tuberculosis, manufactured as 50-mg solid and 25-mg dispersible tablets. We evaluated the effects of dispersing the 50-mg tablet, focusing on the relative bioavailability.
Diacon, Andreas H.,, Mostert, J., Garcia-Prats, A., Veronique de Jager, Diacon, A.H., Svensson, E.M., de Jager, Veronique, de Jager, Veronique,, Jager, V. de, Hesseling, A.C., Anthony Garcia‐Prats, Diacon, Andreas H., Hesseling, Anneke C.,, Zou, Yuanxi,, Yuanxi Zou, Elin M. Svensson, Mostert, Joni,, Joni Mostert, Wiesner, Lubbe, Garcia‐Prats, Anthony, Lubbe Wiesner, Svensson, Elin, Zou, Yuanxi, Wiesner, L., Anneke C. Hesseling, Garcia‐Prats, Anthony,, Andreas H. Diacon, Wiesner, Lubbe,, Svensson, Elin,, Hesseling, Anneke C., Mostert, Joni   +30 more
core   +1 more source

Activity Profiling of Nitro‐Substituted Di(Hetero)Aryl 1,3,4‐ and 1,2,4‐Oxadiazoles: Antimicrobial, Cholinesterase Inhibition and Antioxidant Potential

Archiv der Pharmazie, Volume 359, Issue 1, January 2026.
Novel nitro‐substituted diaryl 1,3,4‐ and 1,2,4‐oxadiazoles were synthesised via molecular hybridisation of bioactive heterocycles. Selected derivatives exhibited potent antimicrobial activity, including against Mycobacterium tuberculosis and Staphylococcus aureus, and cholinesterase inhibitory activity, with promising selectivity.
Enikő Šikorová, Šárka Štěpánková, Eva Frýbová, Klára Konečná, Jana Korbielová, Markéta Švarcová, Ondřej Janďourek, Václav Pflégr, Szilvia Bősze, Martin Krátký   +9 more
wiley   +1 more source